Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07146750 · ClinicalTrials.gov registry record · Phase 1

A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants

A Phase 1 study of Healthy Volunteers, sponsored by Sanofi.

Active
Registry status
Phase 1
Development phase
212
Enrollment target
1
Study location

NCT07146750: Active Phase 1 study of Healthy Volunteers, sponsored by Sanofi.

NCT07146750 is a Phase 1 study of Healthy Volunteers that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 212 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07146750, a Phase 1 study of Healthy Volunteers, is active but no longer recruiting, sponsored by Sanofi.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
212 participants
Enrollment target
1
Study location

Study Summary

This is a single-center, open-label, randomized, single-dose, parallel, Phase 1, 4-arm study designed to determine the bioequivalence and investigate the safety and tolerability profiles of subcutaneous amlitelimab delivered by 2 different devices at 2 different total doses in healthy adult participants.

Primary Outcome

Maximum serum concentration observed.

Conditions Studied

Interventions

  • COMBINATION_PRODUCT SAR445229

Study Locations (1)

Florida

  • Clinical Pharmacology of Miami- Site Number : 8400001 - Miami

Trial Details

FieldValue
Enrollment Target 212 participants
Start Date 2025-08-25
Est. Completion 2026-04-08
Phase Phase 1
Sanofi

713 total trials

What the registry record for NCT07146750 still lists

NCT07146750 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (56% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which SAR445229 is the first listed.

NCT07146750 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT07146750 about?

NCT07146750 is a clinical study titled "A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants". This is a single-center, open-label, randomized, single-dose, parallel, Phase 1, 4-arm study designed to determine the bioequivalence and investigate the safety and tolerability profiles of subcutaneous amlitelimab delivered by 2 different devices at 2 different total doses in healthy adult particip...

What is the current status of trial NCT07146750?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 212 participants. The study started on 2025-08-25. Estimated completion is 2026-04-08.

What conditions does trial NCT07146750 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT07146750?

The interventions under investigation include: SAR445229 (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT07146750?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07146750 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07146750's enrollment target sits among peer trials

212 42nd of 283 higher than 242 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04228978 · 212 participants · NA

    Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

  • NCT04725721 · 212 participants · NA

    Testing FIRST in Youth Outpatient Psychotherapy

  • NCT06257576 · 212 participants · Phase 3

    Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter

  • NCT06456593 · 212 participants · Phase 2

    Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07146750, the US trial registry maintained by the National Library of Medicine. NCT07146750 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.